197 related articles for article (PubMed ID: 30481587)
1. Analysis of post-translational modifications in Alzheimer's disease by mass spectrometry.
Kelley AR; Bach SBH; Perry G
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):2040-2047. PubMed ID: 30481587
[TBL] [Abstract][Full Text] [Related]
2. The Involvement of Post-Translational Modifications in Alzheimer's Disease.
Marcelli S; Corbo M; Iannuzzi F; Negri L; Blandini F; Nistico R; Feligioni M
Curr Alzheimer Res; 2018 Feb; 15(4):313-335. PubMed ID: 28474569
[TBL] [Abstract][Full Text] [Related]
3. Selectively increased oxidative modifications mapped to detergent-insoluble forms of Abeta and beta-III tubulin in Alzheimer's disease.
Boutte AM; Woltjer RL; Zimmerman LJ; Stamer SL; Montine KS; Manno MV; Cimino PJ; Liebler DC; Montine TJ
FASEB J; 2006 Jul; 20(9):1473-83. PubMed ID: 16816122
[TBL] [Abstract][Full Text] [Related]
4. Mass Spectrometry Analysis of Lysine Posttranslational Modifications of Tau Protein from Alzheimer's Disease Brain.
Thomas SN; Yang AJ
Methods Mol Biol; 2017; 1523():161-177. PubMed ID: 27975250
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
6. [Alzheimer's disease: cellular and molecular aspects].
Octave JN; Pierrot N
Bull Acad Natl Med; 2008 Feb; 192(2):323-31; discussion 331-2. PubMed ID: 18819686
[TBL] [Abstract][Full Text] [Related]
7. Protein Semisynthesis Provides Access to Tau Disease-Associated Post-translational Modifications (PTMs) and Paves the Way to Deciphering the Tau PTM Code in Health and Diseased States.
Haj-Yahya M; Lashuel HA
J Am Chem Soc; 2018 May; 140(21):6611-6621. PubMed ID: 29684271
[TBL] [Abstract][Full Text] [Related]
8. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.
Morris M; Knudsen GM; Maeda S; Trinidad JC; Ioanoviciu A; Burlingame AL; Mucke L
Nat Neurosci; 2015 Aug; 18(8):1183-9. PubMed ID: 26192747
[TBL] [Abstract][Full Text] [Related]
9. [Alzheimer disease: cellular and molecular aspects].
Octave JN
Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
[TBL] [Abstract][Full Text] [Related]
10. The hidden players: Shedding light on the significance of post-translational modifications and miRNAs in Alzheimer's disease development.
Singh R; Hussain J; Kaur A; Jamdare BG; Pathak D; Garg K; Kaur R; Shankar S; Sunkaria A
Ageing Res Rev; 2023 Sep; 90():102002. PubMed ID: 37423542
[TBL] [Abstract][Full Text] [Related]
11. Targeting post-translational modifications on tau as a therapeutic strategy for Alzheimer's disease.
Marcus JN; Schachter J
J Neurogenet; 2011 Dec; 25(4):127-33. PubMed ID: 22091726
[TBL] [Abstract][Full Text] [Related]
12. Post-translational modifications within tau paired helical filament nucleating motifs perturb microtubule interactions and oligomer formation.
Acosta DM; Mancinelli C; Bracken C; Eliezer D
J Biol Chem; 2022 Jan; 298(1):101442. PubMed ID: 34838590
[TBL] [Abstract][Full Text] [Related]
13. The molecular bases of Alzheimer's disease and other neurodegenerative disorders.
Maccioni RB; Muñoz JP; Barbeito L
Arch Med Res; 2001; 32(5):367-81. PubMed ID: 11578751
[TBL] [Abstract][Full Text] [Related]
14. N-glycan and Alzheimer's disease.
Kizuka Y; Kitazume S; Taniguchi N
Biochim Biophys Acta Gen Subj; 2017 Oct; 1861(10):2447-2454. PubMed ID: 28465241
[TBL] [Abstract][Full Text] [Related]
15. Modulation of AβPP and GSK3β by Endoplasmic Reticulum Stress and Involvement in Alzheimer's Disease.
Liu XJ; Wei J; Shang YH; Huang HC; Lao FX
J Alzheimers Dis; 2017; 57(4):1157-1170. PubMed ID: 28339396
[TBL] [Abstract][Full Text] [Related]
16. Tau protein directly interacts with the amyloid beta-protein precursor: implications for Alzheimer's disease.
Smith MA; Siedlak SL; Richey PL; Mulvihill P; Ghiso J; Frangione B; Tagliavini F; Giaccone G; Bugiani O; Praprotnik D
Nat Med; 1995 Apr; 1(4):365-9. PubMed ID: 7585068
[TBL] [Abstract][Full Text] [Related]
17. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide.
Yan SD; Yan SF; Chen X; Fu J; Chen M; Kuppusamy P; Smith MA; Perry G; Godman GC; Nawroth P
Nat Med; 1995 Jul; 1(7):693-9. PubMed ID: 7585153
[TBL] [Abstract][Full Text] [Related]
18. Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease.
Ahmed T; Zahid S; Mahboob A; Farhat SM
Curr Neuropharmacol; 2017; 15(4):480-494. PubMed ID: 27012953
[TBL] [Abstract][Full Text] [Related]
19. Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer's Disease.
Wesseling H; Mair W; Kumar M; Schlaffner CN; Tang S; Beerepoot P; Fatou B; Guise AJ; Cheng L; Takeda S; Muntel J; Rotunno MS; Dujardin S; Davies P; Kosik KS; Miller BL; Berretta S; Hedreen JC; Grinberg LT; Seeley WW; Hyman BT; Steen H; Steen JA
Cell; 2020 Dec; 183(6):1699-1713.e13. PubMed ID: 33188775
[TBL] [Abstract][Full Text] [Related]
20. Role of Post-translational Modifications in Alzheimer's Disease.
Ramesh M; Gopinath P; Govindaraju T
Chembiochem; 2020 Apr; 21(8):1052-1079. PubMed ID: 31863723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
